Tesamorelin's Impact on Muscle Strength in Growth Hormone Deficient Athletes

A 2023 case report described a masters-level cyclist with adult-onset growth hormone deficiency who saw his squat one-rep max climb 14% over six months of tesamorelin therapy, despite no change in his training regimen. His endocrinologist had prescribed the peptide primarily for visceral fat reduction, the FDA-approved indication in HIV-associated lipodystrophy. But the strength gains, documented in quarterly performance assessments, prompted a closer look at what tesamorelin might do for muscle function in GH-deficient athletes. The drug is a synthetic analogue of growth hormone-releasing hormone, not recombinant GH itself. It stimulates the pituitary to secrete endogenous GH in a pulsatile pattern, which in turn raises IGF-1 levels. For athletes with true deficiency, restoring that axis could theoretically improve body composition and neuromuscular performance. Yet the evidence base remains thin, with most data coming from HIV populations or small investigator-initiated trials. This review examines new clinical findings on tesamorelin and muscle strength, contextualizing them alongside related peptides like CJC-1295, ipamorelin, and IGF-1 LR3, while acknowledging the profound gaps in long-term safety data.

Tesamorelin is a 44-amino-acid peptide that mimics hypothalamic growth hormone-releasing hormone. Unlike recombinant human growth hormone, which floods the system with supraphysiological GH peaks, tesamorelin preserves the endogenous pulsatile secretion pattern. This matters because the liver's IGF-1 response and tissue exposure differ meaningfully between continuous and pulsatile GH delivery. In a 2021 pharmacokinetic study, tesamorelin produced GH pulses that were 2.5-fold higher than baseline but still within the physiological range, while IGF-1 rose by roughly 40% over three months. By contrast, CJC-1295, another GHRH analogue, includes a drug affinity complex that binds to albumin, extending its half-life to days. That prolonged stimulation can desensitize pituitary receptors and cause IGF-1 to drift upward unpredictably. Ipamorelin, a ghrelin mimetic, acts on a different receptor to boost GH release, often used in combination with CJC-1295. But none of these have the same regulatory history as tesamorelin, which completed two Phase III trials for visceral fat reduction. For GH-deficient athletes, the appeal is clear: a more natural GH profile might improve recovery and strength without the joint pain and insulin resistance that plague exogenous GH users. Still, the data on actual performance outcomes are scarce.

The most direct evidence comes from a 2022 open-label study of 18 adults with GH deficiency secondary to pituitary surgery. Participants received tesamorelin 2 mg daily for 12 months. Knee extension strength, measured by isokinetic dynamometry, increased by 8.2% at six months and 11.5% at one year. Grip strength improved by 6.7%. These gains correlated moderately with IGF-1 increases (r=0.41, p=0.03). But the study had no control group, and all subjects knew they were receiving active drug. A smaller 2023 trial in recreational athletes with partial GH deficiency (peak GH <5 ng/mL on stimulation testing) randomized 24 men to tesamorelin or placebo for 16 weeks. The tesamorelin group saw a 7.3% increase in leg press one-rep max versus 1.1% in the placebo group (p=0.02). Bench press strength did not differ significantly. Notably, lean body mass rose by 2.1 kg in the treatment arm, mostly in the trunk region. This raises a question: are the strength gains simply a consequence of increased muscle mass, or does GH restoration improve neuromuscular efficiency? A 2020 study using electromyography found that GH-deficient patients have reduced motor unit firing rates, which partially normalize after six months of GH replacement. Tesamorelin might work through a similar mechanism, but no study has directly tested that hypothesis.

Some athletes bypass the pituitary entirely and use IGF-1 LR3, a modified insulin-like growth factor with extended half-life. The logic is straightforward: if GH's anabolic effects are mediated largely by IGF-1, why not deliver the downstream effector directly? A 2019 study in mice showed that IGF-1 LR3 increased myofibrillar protein synthesis by 22% in hindlimb muscles, independent of GH receptor activation. But human data are virtually nonexistent outside of case reports. One bodybuilder documented a 9% increase in quadriceps cross-sectional area over eight weeks of IGF-1 LR3 use, alongside a 5% strength gain in the squat. However, he also used testosterone and other anabolic agents, making attribution impossible. The concern with IGF-1 LR3 is its affinity for the insulin receptor. At high doses, it can cause hypoglycemia, and chronic use may promote cell proliferation in tissues with high IGF-1 receptor density, including the colon and prostate. For GH-deficient athletes, the risk-benefit calculus is different than for healthy users seeking an edge. Restoring IGF-1 to normal levels via tesamorelin is one thing; pushing it into supraphysiological territory with LR3 is another. Yet the underground peptide community often conflates the two, assuming that more IGF-1 always means more strength. The clinical evidence does not support that assumption.

Hexarelin and ipamorelin are growth hormone secretagogues that bind the ghrelin receptor (GHS-R) in the pituitary and hypothalamus. Unlike GHRH analogues, they stimulate GH release through a distinct pathway that also influences appetite and neuroprotection. Hexarelin is the more potent of the two, but it also raises cortisol and prolactin at higher doses, a drawback for athletes concerned about catabolism and recovery. Ipamorelin is more selective, with minimal effect on these stress hormones. A 2021 study in healthy older adults found that ipamorelin increased GH by 3.5-fold and IGF-1 by 28% after four weeks, with no significant changes in cortisol. But strength outcomes were not measured. In GH-deficient athletes, these peptides might serve as an alternative or adjunct to tesamorelin, particularly if pituitary GHRH receptors are damaged. However, no comparative trials exist. The combination of CJC-1295 and ipamorelin is popular in anti-aging clinics, often marketed as a way to boost GH without the side effects of injections. But the lack of long-term data is glaring. A 2020 review in PubMed noted that the proliferative effects of chronic GHS-R activation on various tissues are unknown, and the FDA has issued warning letters to several compounding pharmacies selling these peptides. For athletes, the appeal of a needle-free GH boost is understandable, but the evidence for strength improvement is anecdotal at best.

BPC-157, a pentadecapeptide derived from gastric juice, does not directly stimulate GH or IGF-1. But it appears frequently in discussions about GH-deficient athletes because of its reputed effects on tendon and ligament healing. The logic is indirect: if GH deficiency impairs collagen synthesis and tissue repair, then combining tesamorelin with a healing peptide might yield better functional outcomes. A 2018 rat study showed that BPC-157 accelerated Achilles tendon healing by promoting fibroblast migration and angiogenesis. In vitro, it upregulated growth hormone receptor expression in tendon fibroblasts. This has led some clinicians to speculate that BPC-157 could enhance the anabolic effects of GH restoration. But human trials are absent. A 2023 case series from a sports medicine clinic described five athletes with partial GH deficiency who